Advertisement

The Muscular Dystrophies

  • Joline DaltonEmail author
  • Jill S. Goldman
  • Jacinda B. Sampson
Chapter
  • 1k Downloads

Abstract

The muscular dystrophies are heterogeneous group of conditions causing progressive muscle weakness. The dystrophinopathies are caused by mutations in the dystrophin gene, DMD, and include Duchenne muscular dystrophy, Becker muscular dystrophy, and isolated dilated cardiomyopathy. Limb-girdle muscular dystrophies (LGMD) result in progressive proximal muscle weakness and wasting of shoulder and pelvic girdle muscles. The LDMDs are caused by both autosomal dominant and recessive genes. Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant condition with scapular winging and slowly progressive muscle weakness. These and several other muscular dystrophies are discussed in this chapter.

Keywords

Muscular Dystrophy Dystrophin Gene Genetic Counseling Session Becker Muscular Dystrophy Congenital Muscular Dystrophy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

Duchenne Muscular Dystrophy Part 1 (MOV 371491 kb)

Duchenne Muscular Dystrophy Part 2 (MOV 314255 kb)

References

  1. 1.
    Morrison, L. A. (2011). Dystrophinopathies. Handbook of Clinical Neurology, 101, 11–39.PubMedCrossRefGoogle Scholar
  2. 2.
    Perumal, A. R., Rajeswaran, J., et al. (2013). Neuropsychological profile of Duchenne muscular dystrophy. Applied Neuropsychology. Child. 0: 1–9, 2014.Google Scholar
  3. 3.
    Pane, M. L., Lombardo, M. E., Alfieri, P., D’Amico, A., Bianco, F., Vasco, G., et al. (2012). Attention deficit hyperactivity disorder and cognitive function in Duchenne muscular dystrophy: Phenotype-genotype correlation. Journal of Pediatrics, 161(4), 705–709.e1.PubMedCrossRefGoogle Scholar
  4. 4.
    Eagle, M., Baudouin, S. V., Chandler, C., Giddings, D. R., Bullock, R., & Bushby, K. (2002). Survival in Duchenne muscular dystrophy: Improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscular Disorders, 12(10), 926–929.PubMedCrossRefGoogle Scholar
  5. 5.
    Kieny, P., Chollet, S., Delalande, P., Le Fort, M., Magot, A., Pereon, Y., et al. (2013). Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011. Annals of Physical and Rehabilitation Medicine, 56(6), 443–454.PubMedCrossRefGoogle Scholar
  6. 6.
    Flanigan, K. M., Dunn, D. M., von Niederhausern, A., Howard, M. T., Mendell, J., Connolly, A., et al. (2009). DMD Trp3X nonsense mutation associated with a founder effect in North American families with mild Becker muscular dystrophy. Neuromuscular Disorders, 19(11), 743–748.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Gentil, C., Leturcq, F., Ben Yaou, R., Kaplan, J. C., Laforet, P., Pénisson-Besnier, I., et al. (2012). Variable phenotype of del45-55 Becker patients correlated with nNOSmu mislocalization and RYR1 hypernitrosylation. Human Molecular Genetics, 21(15), 3449–3460.PubMedCrossRefGoogle Scholar
  8. 8.
    Flanigan, K. M., Dunn, D. M., von Niederhausern, A., Soltanzadeh, P., Howard, M. T., Sampson, J. B., et al. (2011). Nonsense mutation-associated Becker muscular dystrophy: Interplay between exon definition and splicing regulatory elements within the DMD gene. Human Mutation, 32(3), 299–308.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Witting, N., Duno, M., & Vissing, J. (2013). Becker muscular dystrophy with widespread muscle hypertrophy and a non-sense mutation of exon 2. Neuromuscular Disorders, 23(1), 25–28.PubMedCrossRefGoogle Scholar
  10. 10.
    Acsadi, G., Moore, S. A., Chéron, A., Delalande, O., Bennett, L., Kupsky, W., et al. (2012). Novel mutation in spectrin-like repeat 1 of dystrophin central domain causes protein misfolding and mild Becker muscular dystrophy. Journal of Biological Chemistry, 287(22), 18153–18162.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Soltanzadeh, P., Friez, M. J., Dunn, D., von Niederhausern, A., Gurvich, O. L., Swoboda, K. J., et al. (2010). Clinical and genetic characterization of manifesting carriers of DMD mutations. Neuromuscular Disorders, 20(8), 499–504.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Mercier, S., Toutain, A., Toussaint, A., Raynaud, M., de Barace, C., Marcorelles, P., et al. (2013). Genetic and clinical specificity of 26 symptomatic carriers for dystrophinopathies at pediatric age. European Journal of Human Genetics, 21(8), 855–863.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Brioschi, S., Gualandi, F., Scotton, C., Armaroli, A., Bovolenta, M., Falzarano, M. S., et al. (2012). Genetic characterization in symptomatic female DMD carriers: Lack of relationship between X-inactivation, transcriptional DMD allele balancing and phenotype. BMC Medical Genetics, 13, 73.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Mukherjee, M., Chaturvedi, L. S., Srivastava, S., Mittal, R. D., Mittal, B., et al. (2003). De novo mutations in sporadic deletional Duchenne muscular dystrophy (DMD) cases. Experimental and Molecular Medicine, 35(2), 113–117.PubMedCrossRefGoogle Scholar
  15. 15.
    Yoshioka, M., Yorifuji, T., & Mituyoshi, I. (1998). Skewed X inactivation in manifesting carriers of Duchenne muscular dystrophy. Clinical Genetics, 53(2), 102–107.PubMedCrossRefGoogle Scholar
  16. 16.
    Ferreiro, V., Szijan, I., & Giliberto, F. (2004). Detection of germline mosaicism in two Duchenne muscular dystrophy families using polymorphic dinucleotide (CA)n repeat loci within the dystrophin gene. Molecular Diagnosis, 8(2), 115–121.PubMedCrossRefGoogle Scholar
  17. 17.
    van Essen, A. J., Mulder, I. M., van der Vlies, P., van der Hout, A. H., Buys, C. H., Hofstra, R. M., et al. (2003). Detection of point mutation in dystrophin gene reveals somatic and germline mosaicism in the mother of a patient with Duchenne muscular dystrophy. American Journal of Medical Genetics. Part A, 118A(3), 296–298.PubMedCrossRefGoogle Scholar
  18. 18.
    Muntoni, F., Torelli, S., & Ferlini, A. (2003). Dystrophin and mutations: One gene, several proteins, multiple phenotypes. Lancet Neurology, 2(12), 731–740.CrossRefGoogle Scholar
  19. 19.
    Pegoraro, E., Hoffman, E. P., Piva, L., Gavassini, B. F., Cagnin, S., Ermani, M., et al. (2011). SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. Neurology, 76(3), 219–226.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Swaggart, K. A., & McNally, E. M. (2013). Modifiers of heart and muscle function: Where genetics meets physiology. Experimental Physiology, 99(4), 621–626.PubMedCrossRefGoogle Scholar
  21. 21.
    Ferlini, A., Neri, M., Gualandi, F., et al. (2013). The medical genetics of dystrophinopathies: Molecular genetic diagnosis and its impact on clinical practice. Neuromuscular Disorders, 23(1), 4–14.PubMedCrossRefGoogle Scholar
  22. 22.
    Guglieri, M., Straub, V., Bushby, K., & Lochmüller, H. (2008). Limb-girdle muscular dystrophies. Current Opinion in Neurology, 21(5), 576–584.PubMedCrossRefGoogle Scholar
  23. 23.
    Pena, L., Kim, K., & Charrow, J. (2010). Episodic myoglobinuria in a primary gamma-sarcoglycanopathy. Neuromuscular Disorders, 20(5), 337–339.PubMedCrossRefGoogle Scholar
  24. 24.
    Pegoraro, E., & Hoffman, E. P. (2012). Limb-Girdle muscular dystrophy overview. In: R. A. Pagon, M. P. Adam, T. D. Bird, C. R. Dolan, C. T. Fong, R. J. H. Smith, & K. Stephens (Eds.), GeneReviews™ [Internet]. Seattle, WA, University of Washington, Seattle; 1993–2013. 2000 June 08 [updated 2012 August 30].Google Scholar
  25. 25.
    Eymard, B., & Levy, N. (2012). Diagnostic strategy for limb-girdle muscular dystrophies. Revue Neurologique (Paris), 168(12), 919–926.CrossRefGoogle Scholar
  26. 26.
    Mitsuhashi, S., & Kang, P. B. (2012). Update on the genetics of limb girdle muscular dystrophy. Seminars in Pediatric Neurology, 19(4), 211–218.PubMedCrossRefGoogle Scholar
  27. 27.
    Sarkozy, A., Deschauer, M., Carlier, R. Y., Schrank, B., Seeger, J., Walter, M. C., et al. (2012). Muscle MRI findings in limb girdle muscular dystrophy type 2L. Neuromuscular Disorders, 22(Suppl 2), S122–S129.PubMedCrossRefGoogle Scholar
  28. 28.
    Ghosh, P. S., & Zhou, L. (2012). The diagnostic utility of a commercial limb-girdle muscular dystrophy gene test panel. Journal of Clinical Neuromuscular Disease, 14(2), 86–87.PubMedCrossRefGoogle Scholar
  29. 29.
    Puckelwartz, M., & McNally, E. M. (2011). Emery-Dreifuss muscular dystrophy. Handbook of Clinical Neurology, 101, 155–166.PubMedCrossRefGoogle Scholar
  30. 30.
    Bonne, G., Leturcq, F., & Ben Yaou, R. (2013). Emery-Dreifuss muscular dystrophy. In: R. A. Pagon, M. P. Adam, T. D. Bird, C. R. Dolan, C. T. Fong, R. J. H. Smith, & K. Stephens (Eds.), GeneReviews™ [Internet]. Seattle, WA, University of Washington, Seattle; 1993–2013. 2004 September 29 [updated 2013 January 17].Google Scholar
  31. 31.
    Parmar, M. S., & Parmar, K. S. (2012). Emery-Dreifuss humeroperoneal muscular dystrophy: Cardiac manifestations. The Canadian Journal of Cardiology, 28(4), 516. e511–513.PubMedCrossRefGoogle Scholar
  32. 32.
    van der Maarel, S. M., Miller, D. G., Tawil, R., Filippova, G. N., & Tapscott, S. J. (2012). Facioscapulohumeral muscular dystrophy: Consequences of chromatin relaxation. Current Opinion in Neurology, 25(5), 614–620.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Lamperti, C., Fabbri, G., Vercelli, L., D’Amico, R., Frusciante, R., Bonifazi, E., et al. (2010). A standardized clinical evaluation of patients affected by facioscapulohumeral muscular dystrophy: The FSHD clinical score. Muscle and Nerve, 42(2), 213–217.PubMedCrossRefGoogle Scholar
  34. 34.
    Lutz, K. L., Holte, L., Kliethermes, S. A., Stephan, C., & Mathews, K. D. (2013). Clinical and genetic features of hearing loss in facioscapulohumeral muscular dystrophy. Neurology, 81(16), 1374–1377.PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Wood-Allum, C., Brennan, P., Hewitt, M., Lowe, J., Tyfield, L., & Wills, A. (2004). Clinical and histopathological heterogeneity in patients with 4q35 facioscapulohumeral muscular dystrophy (FSHD). Neuropathology and Applied Neurobiology, 30(2), 188–191.PubMedCrossRefGoogle Scholar
  36. 36.
    van der Maarel, S. M., Deidda, G., Lemmers, R. J., Bakker, E., van der Wielen, M. J., Sandkuijl, L., et al. (1999). A new dosage test for subtelomeric 4;10 translocations improves conventional diagnosis of facioscapulohumeral muscular dystrophy (FSHD). Journal of Medical Genetics, 36(11), 823–828.PubMedCentralPubMedGoogle Scholar
  37. 37.
    Tassin, A., Laoudj-Chenivesse, D., Vanderplanck, C., Barro, M., Charron, S., Ansseau, E., et al. (2013). DUX4 expression in FSHD muscle cells: How could such a rare protein cause a myopathy? Journal of Cellular and Molecular Medicine, 17(1), 76–89.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Richards, M., Coppee, F., Thomas, N., Belayew, A., & Upadhyaya, M. (2012). Facioscapulohumeral muscular dystrophy (FSHD): An enigma unravelled? Human Genetics, 131(3), 325–340.PubMedCrossRefGoogle Scholar
  39. 39.
    Sacconi, S., Lemmers, R. J., Balog, J., van der Vliet, P. J., Lahaut, P., van Nieuwenhuizen, M. P., et al. (2013). The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1. The American Journal of Human Genetics, 93(4), 744–751.CrossRefGoogle Scholar
  40. 40.
    Mitsuhashi, S., Boyden, S. E., Estrella, E. A., Jones, T. I., Rahimov, F., Yu, T. W., et al. (2013). Exome sequencing identifies a novel SMCHD1 mutation in facioscapulohumeral muscular dystrophy 2. Neuromuscular Disorders, 23(12), 975–980.PubMedCrossRefGoogle Scholar
  41. 41.
    Ruegg, S., Lehky Hagen, M., Hohl, U., Kappos, L., Fuhr, P., Plasilov, M., et al. (2005). Oculopharyngeal muscular dystrophy—An under-diagnosed disorder? Swiss Medical Weekly, 135(39–40), 574–586.PubMedGoogle Scholar
  42. 42.
    Banerjee, A., Apponi, L. H., Apponi, L. H., Pavlath, G. K., Corbett, A. H., et al. (2013). PABPN1: Molecular function and muscle disease. FEBS Journal, 280(17), 4230–4250.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Cirak, S., Foley, A. R., Herrmann, R., Willer, T., Yau, S., Stevens, E., et al. (2013). ISPD gene mutations are a common cause of congenital and limb-girdle muscular dystrophies. Brain, 136(Pt 1), 269–281.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Joline Dalton
    • 1
    Email author
  • Jill S. Goldman
    • 2
  • Jacinda B. Sampson
    • 3
  1. 1.Paul and Sheila Wellstone Muscular Dystrophy CenterUniversity of MinnesotaMinneapolisUSA
  2. 2.Taub InstituteColumbia University Medical CenterNew YorkUSA
  3. 3.Department of NeurologyColumbia University Medical CenterNew YorkUSA

Personalised recommendations